<DOC>
	<DOCNO>NCT00590460</DOCNO>
	<brief_summary>The purpose study discover whether child adult Fanconi anemia ( FA ) safely effectively transplant Human Leukocyte Antigen ( HLA ) mismatch ( one haplotype ) , HLA-matched sibling , unrelated donor stem cell , leukocytolytic monoclonal antibody sole condition agent ( patient receive HLA mismatch transplant receive Fludarabine part condition regimen ) . Three monoclonal antibody ( MAb ) use combination . Two , YTH 24 YTH 54 rat antibody direct two contiguous epitope CD45 ( common leucocyte ) antigen . They safely administer part condition regimen 12 patient receive allograft ( HLA match mismatch ) center . They produce transient depletion &gt; 90 % circulate leucocyte . The third MAb Campath 1H , humanize rat anti-CD52 MAb . This MAb widely use treat B cell chronic lymphocytic leukemia ( B-CLL ) recently safely give center part sub-ablative conditioning regimen patient malignant disease . Because MAb produce profound immunosuppression significant , though transient , myelodestruction believe may useful sole condition regimen patient Fanconi anemia , use conventional chemotherapeutic agent condition produce high rate short long term toxicity . We anticipate MAb mediate subablative conditioning permit engraftment high percentage patient little immediate long term toxicity . Campath IH persist vivo several day administration present transplant period deplete donor T cell partial graft versus host disease ( GvHD ) prophylaxis . Additional GvHD prophylaxis provide administration medication FK506 .</brief_summary>
	<brief_title>Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia</brief_title>
	<detailed_description>If clinically feasible ( aplasia , active malignancy ) , recipient marrow harvest cryopreserved back use non-engraftment/rejection follow failure undergo autologous reconstitution . For HLA Mismatched donor , harvest peripheral blood stem cell enrich CD34 cell use Clinimacs CD34 Reagent system . Fludarabine give 5 daily intravenous infusion . Campath-1H give 3 daily intravenous infusion follow Anti-CD45 give four daily intravenous infusion complete two day prior stem cell infusion . Diphenydramine administer intravenously every 4 hour period course infusion . Day -8 Campath 1H per CAGT SOP Fludarabine 30 mg/m2 -7 Campath 1H per CAGT SOP Fludarabine 30 mg/m2 -6 Campath 1H per CAGT SOP Fludarabine 30 mg/m2 -5 YTH 24/54 400ug/kg 6 hr Fludarabine 30 mg/m2 -4 YTH 24/54 400ug/kg 6 hr Fludarabine 30 mg/m2 -3 YTH 24/54 400ug/kg 6 hr -2 YTH 24/54 400ug/kg 6 hr -1 -0 Stem Cell Infusion GVHD prophylaxis achieve positive selection CD34 result &gt; 3 log T cell depletion . Previous report indicate low frequency severe ( Grade II/IV ) GvHD haploidentical transplant recipient receive stem cell population contain &lt; 5 x 10e4 CD3 positive T cell . We hope achieve level CD34 enrichment protocol . However , pharmacologic prophylaxis add CD34 select product contain 5 x 10e4 CD3+ve T cells/kg recipient weight . In addition , Campath 1H persists recipient circulation immediate transplant period contribute anti-GVHD activity , vivo .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis Fanconi Anemia suspect DNA breakage/chromosomal instability syndrome , dyskeratosis congenita Nijmegen breakage syndrome age eligible . Diagnosis Fanconi anemia confirm study peripheral blood bone marrow sensitivity mitomycin C DEB clinical evidence DNA breakage/chromosomal instability syndrome determine genetic test clinical diagnosis geneticist Severe aplasia anemia evidence hypocellular bone marrow least 1 3 criterion : ANC &lt; 500/mm3 Hemoglobin &lt; 10 gm/dl reticulocyte count &lt; 1 % Platelet count &lt; 50,000/mm3 Availability HLA match mismatch ( one haplotype ) family member document Fanconi anemia unrelated HLA match stem cell donor . Fully match define 6/6 match high resolution DR base DNA type . Life expectancy great 6 week limited disease FA Creatinine 2X normal age less Karnofsky score 70 % Patients symptomatic cardiac disease , evidence significant cardiac disease echocardiogram ( i.e. , shorten fraction le 25 % ) . Patients know allergy rat serum product . Patients severe infection evaluation Principal Investigator preclude ablative chemotherapy successful transplantation . Patients severe personality disorder mental illness . Patients document HIV positivity . Pregnant NOTE : Patients would exclude protocol strictly laboratory abnormality include investigator 's discretion approval CCGT Protocol Review Committee FDA Reviewer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
	<keyword>Fanconi Anemia</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>fludarabine</keyword>
	<keyword>campath</keyword>
	<keyword>anti-CD45</keyword>
</DOC>